Ambu — Regulatory Filings 2019

Aug 22, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Ambu has decided to invest further and strengthen its largest market by transitioning sales of aScope™ products from the US distributor. As a result, Ambu will move to a 100% direct sales organisation for pulmonary endoscopy in the US. Financial guidance is revised.

Since 2015, Ambu and Tri-anim Health Services, a leading US specialty distributor, have been in partnership to make Ambu’s single-use bronchoscopes the market leader. Today, Tri-anim covers 40% of Ambu’s revenue from sales of aScope™ products within pulmonary endoscopy in the US market. As part of the ongoing initiative to expand our direct sales force, Ambu and Tri-anim have mutually agreed to fully transition the sales of aScope™ products to Ambu.

“We are confident that with our pipeline of new endoscope products in markets including ENT and urology, we will be able to maximise revenue growth and cross-sales effects by going direct. This is an attractive investment for Ambu as transition effects will be outweighed by higher long-term growth,” says CEO of Ambu Juan Jose Gonzalez.

Read more in the attached company announcement.

Contacts

Investor relations

CFO, Michael Højgaard, [email protected] or +45 4030 4349

IR Manager, Nicolai Thomsen, [email protected] or +45 2620 8047

Media

Morten Huse Eikrem-Jeppesen, [email protected] / +45 5385 0770

Attachment

• Company announcement no. 13 2018_19